Baxter International (BAX) : 12 analysts are covering Baxter International (BAX) and their average rating on the stock is 2.94, which is read as a Hold. 1 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 2, which recommends a Buy affirms that they expect a large upside in the stock from the current levels. However, 1 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. A total of 10 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Baxter International (BAX) : The highest short term price target forecast on Baxter International (BAX) is $60 and the lowest target price is $46. A total of 8 equity analysts are currently covering the company. The average price of all the analysts is $50 with a standard deviation of $4.5.
Company shares have received an average consensus rating of Hold for the current week Baxter International (NYSE:BAX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $48.61 and $48.60 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $49.49. The buying momentum continued till the end and the stock did not give up its gains. It closed at $49.03, notching a gain of 0.88% for the day. The total traded volume was 3,499,862 . The stock had closed at $48.60 on the previous day.
In a related news, Almeida Jose E, CEO of Baxter International Inc had purchased 11,691 shares on May 23, 2016 in a transaction. The price per share was $42.75 and the total amount of the disclosed transaction was $499,790.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.
Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.